Magnesium L-Threonate Lifted Oura Deep and REM Scores in 3 Weeks
A 2024 randomized trial tested a brain-targeted form of magnesium, magnesium L-threonate (Magtein), in 80 adults with sleep complaints. After 21 days at 1 g/day, the MgT group had better Oura deep and REM sleep scores than placebo, along with improved mood, energy and alertness. But the placebo group also got worse, the sleep staging came from a consumer wearable, and the study never compared threonate to glycinate or citrate. Here's what the trial actually shows, what a 1 g dose really delivers in elemental magnesium, and where the caveats lie.
Berberine vs. Metformin: The Pilot Trial Behind HbA1c 9.5% to 7.5%
A small 2008 pilot trial put berberine head-to-head with metformin in newly diagnosed type 2 diabetes, and the glucose-lowering effect looked similar. In the berberine group, HbA1c fell from 9.5% to 7.5% in three months. A second trial in 48 people already on treatment saw HbA1c drop from 8.1% to 7.3% and HOMA-IR fall 44.7%. But these were small studies in people with diabetes, and about a third of participants had GI side effects. Here is what the data show, what they don't, and what to know before you think about berberine.
Vitamin D3 Preserved 140 Base Pairs of Telomere in a 4-Year RCT
A large, randomized, placebo-controlled trial found that four years of vitamin D3 slowed telomere shortening by about 140 base pairs. The data come from the VITAL study of older U.S. adults taking 2,000 IU/day. The effect was modest and borderline significant (p=0.039), and telomere length is a surrogate marker, not proof of a longer life. Omega-3s, meanwhile, did nothing for telomeres in this trial. Here is what the numbers show, what the limits are, and how to use the finding sensibly.
2.5 g of Collagen Peptides Cut Eye Wrinkles 20% in 8 Weeks
Collagen is one of the most searched beauty and longevity supplements, but few products have placebo-controlled human data. In this trial of 114 women aged 45-65, 2.5 g a day of the specific bioactive peptide Verisol cut eye wrinkle volume by 20% versus placebo after 8 weeks. Biopsies showed 65% more procollagen type I and 18% more elastin, while a 6% fibrillin bump wasn't significant. The effect was still detectable 4 weeks after the last dose. But the results apply to one branded peptide in one population, not every collagen powder, so here's what the paper does and doesn't prove.
Calcium Alpha-Ketoglutarate Extended Female Mouse Lifespan by Up to 16.6%. Here's What That Does (and Doesn't) Mean for Humans
A 2020 Cell Metabolism study found that feeding middle-aged mice a 2% calcium alpha-ketoglutarate diet extended female median lifespan by up to 16.6% and reduced frailty. The effect was smaller in the second cohort (10.5%), and male survival gains were not statistically significant. Researchers link the benefit to lower systemic inflammation and a proposed rise in IL-10. But this was a mouse-only study, and it does not establish that AKG extends human lifespan. Here is what the data show, how they differ from supplement marketing, and why CaAKG belongs on a research watchlist rather than in a proven protocol.
Spermidine for Memory? A 12-Month Trial in 100 Older Adults Found No Edge Over Placebo
Spermidine has been hyped as a brain-protecting supplement on the strength of autophagy research and animal studies. The SmartAge trial put it to a rigorous test in 100 older adults with subjective cognitive decline, giving about 0.9 mg per day for 12 months. The primary memory outcome did not beat placebo (difference -0.03; P = .47), and secondary outcomes were also null. Exploratory hints on inflammation and verbal memory remain unconfirmed. Here is what the result means for anyone considering a spermidine supplement, and where the study's limits lie.
1,000 mg of Nicotinamide Riboside Daily Raised Blood Cell NAD+ by About 60% in Older Adults, Randomized Trial Finds
A 2018 Nature Communications crossover trial tested nicotinamide riboside at 500 mg twice daily (1,000 mg/day) for six weeks in healthy middle-aged and older adults. The supplement was well tolerated and raised NAD+ in blood immune cells by about 60% compared with placebo. Researchers also saw early signals for lower blood pressure and arterial stiffness, which they flagged as ideas for larger trials, not proven benefits. This article explains why NAD+ is thought to fall with age, what the study did, and what it cannot tell us about disease outcomes or longevity.
NMN's First Human Win: 250 mg a Day Lifted Muscle Insulin Sensitivity by About 25% in Prediabetic Women
NMN has long been a darling of the longevity market, but human evidence was thin until a 2021 Washington University trial published in Science. In postmenopausal women with prediabetes who were overweight or obese, 250 mg of NMN daily for 10 weeks improved muscle insulin sensitivity by roughly 25%. Muscle insulin signaling and genes tied to muscle remodeling also improved, while the placebo group saw no change. But the benefit was narrow, and the study did not show NMN lowering blood sugar or reversing prediabetes. Here's what the trial found, who it applies to, and what it didn't change.
Taurine, the Cheap Amino Acid That Stretched Mouse Lifespans by Up to 12%, Falls With Age in Humans
A 2023 Science study found that circulating taurine, a cheap and widely available amino acid, declines with age in mice, monkeys and humans. Supplementing middle-aged mice extended median lifespan by roughly 10-12% and improved healthspan in both rodents and monkeys. The compound appeared to curb cellular senescence, DNA damage, mitochondrial dysfunction and inflammaging. Human data remain observational, and the mouse doses scale to several grams a day, so the evidence is far from proof. Here is what the study showed, what doses people have discussed, and why researchers say trials are needed before anyone treats taurine as an anti-aging pill.